Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01745913 · ClinicalTrials.gov registry record · Phase 2
Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies
A Phase 2 study, sponsored by Weill Medical College of Cornell University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT01745913 is a Phase 2 study that was terminated before completion, run by Weill Medical College of Cornell University. The registered enrollment target is 2 participants.
The verdict
NCT01745913, a Phase 2 study, was terminated before completion, sponsored by Weill Medical College of Cornell University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of this study is compare the efficacy of haplo-cord transplant (investigational arm) with that of a more commonly used procedure in which only the cells contained in one or two umbilical cords are infused (standard arm). We hypothesize that reduced intensity conditioning and haplo-cord transplant results in fast engraftment of neutrophils and platelets, low incidences of acute and chronic graft versus host disease, low frequency of delayed opportunistic infections, reduced transfusion requirements, shortened length of hospital stay and promising long term outcomes. We also hypothesize that umbilical cord blood selection can prioritize matching and better matched donors can be identified rapidly for most subjects.
Interventions
- DRUG Fludarabine
- DRUG Melphalan
- DRUG Rabbit ATG
- DEVICE CliniMACS® CD34 Reagent System
- PROCEDURE Double Umbilical Cord Blood Transplantation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2012-10-26 |
| Est. Completion | 2015-04-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01745913
The ClinicalTrials.gov registry entry for NCT01745913 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Fludarabine is the first listed.
NCT01745913 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01745913 about?
NCT01745913 is a clinical study titled "Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies". The purpose of this study is compare the efficacy of haplo-cord transplant (investigational arm) with that of a more commonly used procedure in which only the cells contained in one or two umbilical cords are infused (standard arm). We hypothesize that reduced intensity conditioning and haplo-cord ...
What is the current status of trial NCT01745913?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2012-10-26. Estimated completion is 2015-04-29.
What interventions are being tested in trial NCT01745913?
The interventions under investigation include: Fludarabine (DRUG), Melphalan (DRUG), Rabbit ATG (DRUG), CliniMACS® CD34 Reagent System (DEVICE), Double Umbilical Cord Blood Transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT01745913?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.